Peking University: Esophageal Neoplasms trials
The registry lists 11 Esophageal Neoplasms studies with Peking University as lead sponsor. 6 are open to participants now and 0 have results posted.
Phase 1 2Phase 2 6Phase 3 2Phase 4 1No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With ImmunochemotherapyNot yet recruitingNCT06963593Phase 4
- Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma PatientsNot yet recruitingNCT06857786Phase 1
- A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal CancerNot yet recruitingNCT06745193Phase 2
- Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06353152Phase 1
- Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal CancerRecruitingNCT05866510Phase 2
- A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal CancerNot yet recruitingNCT04616040
- Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric AdenocarcinomaStatus unknownNCT02193594Phase 2/3
- Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal CancerTerminatedNCT01704690Phase 2/3
- Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)Active, not recruitingNCT01688908Not applicable
- mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the EsophagusStatus unknownNCT01486992Phase 2
- mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical TrialStatus unknownNCT01044420Phase 2